Cellebrite Names David Barter Chief Financial Officer
David Barter, Cellebrite Chief Financial Officer
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 08, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced that David Barter, a proven finance executive with extensive public company CFO experience in technology and software, has been appointed CFO, effective immediately. He succeeds Dana Gerner, who has served as Cellebrite's CFO since 2014. Gerner will remain in an active advisory role to support the transition until the Company reports its second-quarter 2025 financial results. As CFO, Barter is responsible for the Company's financial operations, including financial planning, accounting, reporting and treasury, as well as corporate development, investor relations and operations. He reports directly to CEO Thomas E. Hogan.
'On behalf of the full board, our employees, and our shareholders, I want to thank Dana Gerner for her dedication, professionalism, passion and performance. For the past eleven years, Gerner led a high-caliber finance and operations organization and played a key role in building Cellebrite into a market-leading public company, delivering consistently strong top-line growth, profitability and cash generation,' stated Hogan. 'The Company owes Dana an enormous debt of gratitude and wishes her every success as she embarks on a new and exciting chapter in her life.'
Hogan continued, 'We are thrilled to welcome Dave to Cellebrite. Dana set a high bar for her successor. We sought a leader with proven experience as a public company software CFO focused on growth and operations at scale, exceptional leadership skills, strong communication acumen and US-based with a track record of leading and operating globally.'
'It has been a great privilege to be part of Cellebrite's journey. We have accomplished a lot over the past 11 years, and the company has a bright future. I have no doubt that the team, under Dave's leadership, will continue to positively contribute to Cellebrite's success,' said Dana Gerner.
Barter brings more than three decades of public company financial leadership experience. For the last 20 years, he has been focused on scaling global software companies. Prior to joining Cellebrite, he served as CFO at New Relic where he played an instrumental role in driving the company's growth to nearly $1 billion in annual revenue, transitioning the company to a consumption-based model, improving profitability and cash flow and supporting a successful $6.5 billion sale of the business. Barter previously served as CFO at C3.ai and Model N as well as held senior finance positions at Guidewire Software, Microsoft and General Electric.
'I could not be more excited to join Cellebrite,' stated David Barter. 'The Company's unique and compelling mission and focus on public safety captured my interest and fuels my ongoing enthusiasm about joining Cellebrite. Every day, Cellebrite's technology makes a tangible difference in helping thousands of customers around the globe elevate their operational intelligence and accelerate their investigations in ways that make our world safer. I look forward to working with Cellebrite's leadership team as well as my new colleagues to effectively and efficiently expand our business around the world and deliver on our commitments to our customers, communities, employees and shareholders.'
Cellebrite will report its second-quarter 2025 financial results before market open on Thursday, August 14, 2025. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's quarterly financial results, introduce Dave Barter and provide an update on important strategic initiatives including the recently announced acquisition of Corellium. Relevant details include:
Date:
Thursday, August 14, 2025
Time:
8:30 a.m. ET
Call-In Number:
203-518-9783 / 800-267-6316
Conference ID:
CLBTQ225
Event URL:
https://investors.cellebrite.com/events/event-details/cellebrite-q2-2025-financial-results-conference-call-webcast
Live Webcast URL:
https://edge.media-server.com/mmc/p/8rnat9mu/
In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company's investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.
References to Websites and Social Media PlatformsReferences to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
About CellebriteCellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite's AI-powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite's digital forensic and investigative solutions—available via cloud, on-premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com/investors and find us on social media @Cellebrite.
Caution Regarding Forward Looking Statements
This document includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'will,' 'appear,' 'approximate,' 'foresee,' 'might,' 'possible,' 'potential,' 'believe,' 'could,' 'predict,' 'should,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Successful completion of the Company's quarterly financial close processes and the successful transition of the CFO role at the Company; Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled 'Risk Factors' in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ('SEC'), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Contacts:
Investors RelationsAndrew KramerVice President, Investor Relationsinvestors@cellebrite.com+1 973.206.7760
Media Jackie Labrecque Sr. Manager of Content Strategy and Operations Jackie.labrecque@cellebrite.com+1 771.241.7010
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6512336b-30e9-457b-8228-c1da62535887Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
28 minutes ago
- Business Wire
Priority Health Expands into Wisconsin by Becoming Governing Member of Group Health Cooperative of Eau Claire
BUSINESS WIRE)--Priority Health, a Michigan-based health plan serving more than 1.3 million members, and Group Health Cooperative of Eau Claire (the Cooperative), a community-based health plan in Wisconsin serving more than 61,000 members, have announced plans for Priority Health to become the governing member of the Cooperative. "By bringing together our strengths and capabilities, we are better positioned to improve health outcomes and provide an exceptional member experience." 'This agreement with Group Health Cooperative of Eau Claire marks a significant milestone in our mission to expand access to high-quality, affordable health care to those we are privileged to serve,' said Nick Gates, interim president of Priority Health. 'By bringing together our strengths and capabilities, we are better positioned to improve health outcomes and provide an exceptional member experience. We look forward to serving the members of Group Health Cooperative of Eau Claire.' Sarah North, CEO and general manager of Group Health Cooperative of Eau Claire, said: 'Priority Health brings a track record of thoughtful leadership and a deep commitment to improving health outcomes — qualities that align well with our values. This agreement lays the groundwork for continued growth and innovation in today's rapidly evolving health care landscape and positions us for long-term sustainability while allowing us to stay true to our purpose of improving health and offering community-based health plans in Wisconsin.' Both organizations anticipate the transaction will close by the end of 2025 after required approvals are completed. The agreement with the Cooperative will make Priority Health a four-state health plan. In December 2024, Priority Health became the sole member of Physicians Health Plan of Northern Indiana, which serves members in Indiana and Ohio. Kaufman, Hall, and Associates, LLC is serving as exclusive strategic and financial advisor and Weld Riley is serving as legal counsel to Group Health Cooperative Eau Claire in this transaction. Taft Stettinius & Hollister is serving as external legal counsel to Priority Health and Ankura is serving as due diligence advisor. About Priority Health: Our members are at the heart of everything we do. With more than 30 years in business, Priority Health is the second-largest health plan in Michigan and the third-largest provider-sponsored health plan in the nation, offering an extensive portfolio of health benefits options for employer groups and individuals, including Medicare and Medicaid plans. Serving more than 1.3 million members each year in Michigan, Indiana and Ohio, Priority Health offers a broad network of primary care physicians. Priority Health continues to be recognized as a leader for quality, customer service, transparency and product innovation. Learn more about affordable, quality health coverage options from Priority Health. Visit the Priority Health newsroom for the latest news. About Group Health Cooperative of Eau Claire: Founded in 1972, Group Health Cooperative of Eau Claire is a nonprofit, member-focused health plan serving approximately 61,000 members across Wisconsin, including Medicaid and Medicare beneficiaries, commercial employer groups, and state employees. Visit Group Health Cooperative of Eau Claire to learn more.
Business Insider
29 minutes ago
- Business Insider
Where to invest $10,000 right now, according to 6 Wall Street heavyweights
If you have $10,000 in cash waiting to be invested, you probably wish you had shoveled that money into the stock market in mid-April. But you're not the first, and won't be the last, investor who missed a good entry point into the market. Even with the market at all-time highs since hitting a bottom in April, that doesn't mean it's a bad time to jump in. Six Wall Street veterans told Business Insider that there are still plenty of pockets of opportunity. Some, for example, still like tech stocks as AI investment booms. Some of those same people also think it's smart to hedge and diversify right now amid the hype and lofty valuations. They recommend allocating some money to areas like value or international stocks. There's no one-size-fits-all approach to investing. Figuring out where to put your money depends on your individual circumstances, like your investment timeline and risk tolerance. For this hypothetical thought exercise, we asked our sources where they themselves would invest the money if they suddenly came into $10,000. Gabriela Santos, chief strategist for the Americas at JPMorgan Santos said that if she were gifted $10,000 right now, she would invest $7,000 in developed-market ex-US stocks and the remaining $3,000 in emerging-market stocks. "After 15 years of disappointment, it's really been all about international equities this year — huge outperformance, and something we see as just the beginning," Santos said. Santos is still bullish on US stocks, but said that international stocks are primed for relative outperformance given how high valuations are on US stocks. Historically, US stocks have traded at a 15% premium to international stocks, but now trade at a 35% premium. Plus, the value of the US dollar has fallen in recent months, and demand for ex-US assets has risen. "For someone, maybe like me, who's been too concentrated just on the US equity story, I think we've really seen a huge turning point to put some of that money to work overseas finally," she said. Two examples of exchange-traded funds that offer exposure to these areas include the Vanguard FTSE Developed Markets ETF (VEA) and the iShares MSCI Emerging Markets ETF (EEM). Year-to-date, the funds are up 19.7% and 18.6%, respectively. Barry Bannister, chief US equity strategist at Stifel Bannister identified three baskets of opportunities: value stocks, small-caps, and international stocks. For value stocks, he said to go with a large-cap value fund like the Vanguard Value ETF (VTV). For small-caps, the iShares Russell 2000 ETF (IWM) works well for its broad-based nature having exposure to the growth and value factors, Bannister said. And for international stocks, Bannister like the iShares MSCI ACWI ex US ETF (ACWX). These trades provide diversification from a tech-concentrated market, Bannister said. "Right now the market's obsessively focused on tech. But it's hard to run an economy on seven stocks," Bannister said, referring to the so-called Magnificent Seven stocks. Bannister said he recently put long-term bets on these trades himself. "I actually put a third, a third, a third, into small-cap, international, and value on some money that came in in May that I got, and we'll see how it works out for 10 years," he said. Hank Smith, CIO at Haverford Trust Normally, Smith would simply recommend a broad market index so that your money is well diversified. There's only one problem with that: most main indexes aren't all that diversified at the moment, with the so-called Magnificent Seven stocks making up almost a third of the S&P 500. So Smith has an easy fix: Put 50-60% of the money into an equal-weight S&P 500 fund, like the Invesco S&P 500® Equal Weight ETF (RSP), rather than the more widely followed market cap-weighted index. The equal-weight product gives you the same exposure to all 500 companies in the index instead of adjusting for exposure by company size. The equal-weight index has generally underperformed over the last five years, but it would hypothetically suffer less downside in a tech sell-off. The remaining 40-50% of the money can go into a more concentrated cap-weighted index like the tech-heavy Nasdaq 100, Smith said. That way, you don't miss out too much if the tech rally keeps ripping. "Now you get all your top tech holdings that are driving this market," he said. Smith's suggestions assume at least a five-year timeline. Michael Kantrowitz, chief investment officer at Piper Sandler Unlike Santos, Kantrowitz is still bullish on the American exceptionalism theme and would continue to bet on the US stock market for the next few years. Kantrowitz doesn't have a specific sector slant — he recommends investing in large-cap profitable leaders within their industries. "The earnings backdrop is going to be very bifurcated, and interest rates are going to remain elevated," Kantrowitz said of the next few years. With this backdrop, existing large-cap winners will continue to perform and have better earnings revisions than their peers. Kantrowitz would avoid passive sector indexes like a broad tech ETF, as those often don't accurately reflect the performance of the underlying basket of stocks due to weighting criteria. Instead, he recommends a more active stock-picking approach. The largest names that are screening well in Piper Sandler's models include Big Tech names — unsurprisingly, Nvidia, Microsoft, Alphabet, and Meta make the list — and companies like Oracle, Costco, Johnson & Johnson, and Home Depot. Tony DeSpirito, head of US fundamental equities at BlackRock DeSpirito, who manages several funds with a focus on combining value and quality, would split his investment between large-cap growth companies, dividend stocks, and value stocks. His guiding principle is building a well-diversified portfolio that can weather market volatility, given tariff headlines. The S&P 500 has undoubtedly become more expensive and growth-oriented thanks to the dominance of tech, but it's still a good idea to maintain exposure to Big Tech, according to DeSprito. "I'm not negative on the Mag Seven," DeSpirito said. "Many of them have really good growth and really good free cash flow. That's an incredibly powerful combination, and so they earn the multiples that they're trading at." For diversification, dividend stocks tend to be more resilient during downturns and provide a steady stream of income. DeSpirito is also on the hunt for unloved stocks that are trading cheaply. Healthcare companies are an especially compelling opportunity at the intersection of value and quality, according to DeSpirito. This area of the market has been largely ignored by investors, with the S&P 500 healthcare sector down 2% year-to-date. DeSpirito likes medical device companies, as these trade at mid-teens earnings ratios with good growth prospects. However, some large-cap pharmaceutical companies could be value traps, as their earnings are heavily dependent on patents, DeSpirito warned. Lara Castleton, US head of portfolio construction and strategy at Janus Henderson For investors with a longer timeline and a higher risk tolerance, Castleton suggested a three-pronged approach in equities. First, plug around 60% of your funds into large-cap stocks with a bias toward tech. Despite its comeback rally after a sharp dip earlier this year, tech is "still one of the areas and sectors that's going to dominate the markets for the next 10 years" given the innovation coming out of the sector, Castleton said. There are multiple ways to get exposure to the tech theme, but some general example funds might include the Technology Select Sector SPDR Fund (XLK) and the Invesco QQQ Trust (QQQ). Second, put about 20% of the fund into ex-US stocks. International stocks have gotten a big boost this year amid Trump's trade war and initial pullback from US support in Ukraine, and Castleton thinks the rally can continue. "You have to have some of that diversification because I truly believe going forward that you'll continue to see value coming out of Europe, some of these ex-US players that are now all of a sudden shifting their mentality to spending more on defense, to deregulating their companies," she said. Third, Castleton said to put the remaining 20% into mid-cap stocks, or companies with a market cap between $2 and 10 billion. This can provide further portfolio diversification, Castleton said, but the stocks should also benefit from reshoring as the deglobalization trend continues. "They're more domestically-oriented companies, and they also have a lot more room to grow than the large caps that have already kind of established their business models," she said.
Business Insider
29 minutes ago
- Business Insider
'A long, slow bleed': Quant hedge funds are getting slammed and scrambling for answers
Quant hedge fund managers are experiencing one of the most prolonged droughts in recent memory. The bigger concern: They don't know why. Systematic hedge funds have suffered a steady decline since June that managers are struggling to wrap their heads around. Quant executives, portfolio managers, and headhunters working in the space told Business Insider that the turmoil has hit most of the industry, generating concern and intrigue about the source of the pain. "It kinda crept up on everyone as there weren't many disastrous days, but it's been small loss after small loss," said one executive at a quant trading firm, who wasn't authorized to speak publicly. "No one seems to know why this is happening." Qube Research & Technologies, the $28 billion quant firm started by former Credit Suisse traders, has lost 5% in July in its flagship fund through last Friday, a person close to the manager said. The manager's larger Torus fund is down 7% in July, but both strategies are still up double-digits on the year. Point72's Cubist unit has experienced one of its worst stretches since the pandemic slammed global markets in March 2020, two people familiar with the firm said. Two Sigma's Spectrum fund is down roughly 2% this month through the end of last week, a person close to the manager said. At Man Group, the firm's AHL Dimension fund — a multi-asset systematic strategy — was down 2.5% in July through Tuesday, according to the London-based manager's website. Renaissance Technologies' largest external fund was down close to 6% in June, according to HSBC's Hedge Weekly report. These firms declined to comment or did not immediately respond to requests for comment. From the start of June through this Tuesday, equity quant managers lost 4.2%, according to a report from Goldman Sachs' prime services unit. The losses, driven by US equities, are the worst run of performance for systematic long-short strategies since a sharp drop at the end of 2023. Quant distress doesn't necessarily signal broader market trouble, but severe losses can spill over — especially if a large firm dumps positions and sparks contagion. The S&P 500 is up nearly 8% since June, and the VIX — a measure of volatility — is at its lowest point since February. Other prominent hedge fund strategies, including fundamental equity and multi-strategy, have steadily gained over the same period, the report said. Luckily for the quant space, it had been a strong year performance-wise until summer began, so the sector's annual returns are still, on average, outpacing their human rivals. A hallmark of statistical arbitrage, a classic quant trade that wields mathematical models to exploit short-term pricing inefficiencies across large baskets of stocks, istaking positions poised to pay off regardless of broader market swings. It has periodic slumps like any other trade, but they tend to be sharp and quick. Major drawdowns often last just a couple of days and stem from a large player liquidating a portfolio or reducing market exposure. Overcrowding can exacerbate losses, as it did during the so-called Quant Quake, in which systematic hedge funds such as Goldman Sachs' famed quantitative division suffered heavy, sudden losses in August 2007 while the rest of the market rallied. What's unusual this summer, industry sources say, is the accumulation of small losses over weeks. "Everyone says it's different this time — different because of duration," said a hedge fund consultant who works with large quant funds. "This has been a long, slow bleed across the complex." That pattern isn't consistent with a large liquidation and its aftershocks, though losses so far this week have been more intense, including a 0.6% decline on Tuesday, according to Goldman Sachs. The Goldman report said drivers included the sell-off of momentum strategies that bet rising stocks will keep rising; the rally in speculative, high volatility stocks; and "some unwinding of crowded trades." Intense losses could quickly pile up if sizable funds start cutting their exposure. "It's survival of the fittest, basically," said one quant trader at a multi-billion-dollar manager. "Who is going to have the stomach to ride this out and stick to their bets?"
